SML3857
Etamicastat
≥98% (HPLC)
别名:
(R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione, (R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, 5-(2-Aminoethyl)-1-[(3R)-6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-yl]-1,3-dihydro-2H-iImidazole-2-thione, BIA 5-453
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C14H15F2N3OS
化学文摘社编号:
分子量:
311.35
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Orally active, potent, reversible and peripherally selective dopamine-β-hydroxylase (DBH) inhibitor.
Etamicastat (BIA 5-453) is an orally active, potent, reversible and peripherally selective dopamine-β-hydroxylase (DBH) inhibitor that reduces both systolic (SBP) and diastolic (DBP) blood pressure.
Etamicastat (BIA 5-453) is an orally active, potent, reversible and peripherally selective dopamine-β-hydroxylase (DBH) inhibitor that reduces both systolic (SBP) and diastolic (DBP) blood pressure.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453)
Drugs in R&D, 11(2), 127-136 (2011)
Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-?-hydroxylase: comparison with nepicastat
European Journal of Pharmacology, 751, 50-58 (2015)
Dopamine ? hydroxylase as a potential drug target to combat hypertension
Expert Opinion on Investigational Drugs, 29(9), 1043-1057 (2020)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持